News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Actelion Ltd. (ALIOF.PK) Lifts Profit View On Strong Start For New Drug



2/11/2014 7:04:38 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Actelion, Europe's biggest biotech company, raised its 2014 earnings forecast on Tuesday, encouraged by a strong launch for its new heart and lung drug and better-than-expected profit for last year. The Swiss company has seen its prospects brighten after regulators in Europe and the United States approved its big drug hope Opsumit, a treatment for pulmonary arterial hypertension (PAH), at the end of last year. It is banking on Opsumit to cut its dependence on mainstay drug Tracleer, which makes up around 86 percent of sales, but loses patent protection from 2015 and has faced growing competition from Gilead's Letairis.

Help employers find you! Check out all the jobs and post your resume.

Read at Reuters
Read at Bloomberg
Read at Market Watch
Read at Wall Street Journal


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES